P/E at 29.55 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.55 for Dr Reddys Laboratories Ltd represents a discount of approximately 20.3% relative to the sector’s average of 37.05. This valuation gap suggests the market is pricing in either subdued growth prospects or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations due to steady earnings and innovation potential, this discount merits closer scrutiny. Dr Reddys Laboratories Ltd’s mid-cap status with a market capitalisation of ₹95,099.26 crores places it among sizeable industry players, yet the valuation differential may reflect recent operational or market challenges.

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple horizons reveals a nuanced picture. Over the past year, the stock has declined by 12.59%, underperforming the Sensex’s 8.94% fall. The year-to-date return of -10.36% is marginally better than the Sensex’s -12.87%, indicating some relative resilience earlier in the year. However, the three-month period stands out with a -10.64% return, sharply contrasting with the Sensex’s positive 0.57%. This recent weakness is compounded by a five-day loss of 1.65% over three consecutive sessions, signalling sustained selling pressure. Dr Reddys Laboratories Ltd’s short-term underperformance raises questions about the catalysts behind this momentum shift — is this a temporary correction or indicative of deeper structural issues?

Moving Average Configuration: Bearish Technical Setup

The technical landscape for Dr Reddys Laboratories Ltd is decidedly bearish. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — a configuration that typically signals a downtrend or prolonged weakness. This alignment suggests that short-term rallies may face resistance, and the stock remains under pressure from a technical standpoint. The proximity to its 52-week low, just 4.63% away at Rs 1080.05, further emphasises the fragile price environment. Could this be a prelude to a sustained recovery or a continuation of the downtrend?

Relative Performance Versus Sensex

When compared to the Sensex, Dr Reddys Laboratories Ltd has consistently lagged over the medium to long term. Its three-year return of 1.50% is significantly below the Sensex’s 10.62%, while the five-year return of 15.92% trails the Sensex’s 27.36%. Even over a decade, the stock’s 78.42% gain is less than half the Sensex’s 157.86%. This persistent underperformance highlights challenges in maintaining growth momentum relative to the broader market. However, the stock’s one-month return of -5.45% is only slightly worse than the Sensex’s -4.99%, and the one-week loss of -1.27% is less severe than the Sensex’s -2.95%, suggesting some short-term relative strength despite the overall downtrend.

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution indicates a broadly stable sector environment with pockets of weakness. Dr Reddys Laboratories Ltd’s recent underperformance contrasts with the sector’s overall resilience, raising questions about company-specific factors impacting its share price. Is the stock’s lagging performance a reflection of internal challenges or broader sector headwinds?

Rating Reassessment and Historical Context

Previously rated Hold by MarketsMOJO, Dr Reddys Laboratories Ltd had its rating updated on 13 Jul 2026. The current Mojo Score stands at 30.0, with a Mojo Grade of Sell, reflecting a more cautious stance. This shift aligns with the stock’s recent price weakness and technical indicators. The rating change invites investors to reconsider their positions — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Conclusion: A Complex Data-Driven Picture

The data on Dr Reddys Laboratories Ltd paints a multifaceted picture. Its valuation discount to the sector average contrasts with persistent underperformance across medium and long-term horizons. The technical setup remains weak, with the stock trading below all major moving averages and near its 52-week low. Sector results show a mixed environment, with the company’s recent struggles standing out. The rating reassessment from Hold to a more cautious grade reflects these challenges. Taken together, these factors highlight the importance of analysing multiple data points before drawing conclusions — what is the current rating for Dr Reddys Laboratories Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →